Notice of Annual General Meeting of Brain+ A/S and Change to the Board of Directors
Invitation to Annual General Meeting
The shareholders of Brain+ A/S are hereby invited to attend the Annual General Meeting scheduled for 18th May 2022, 14:00. The general meeting will be take place at Hauser Pl. 20, 5., 1127 København as a physical event.
Attached please find the invitation, agenda and appendices for the Annual General Meeting.
As previously announced by the Company, Kim Arvid Nielsen has decided to step down from the Board in order to focus full time on his medical practice. Consequently, he is not standing for re-election at the Annual General Meeting on 18th May. The Company is actively seeking a replacement director to join the Board. A further announcement will be made as soon as that process is concluded.
For additional information regarding registration, proxy and postal votes please visit www.brain-plus.com/investor.
Contact Information
CEO, Kim Baden-Kristensen + 45 31393319, E-mail: kim@brain-plus.com, Brain+ A/S, Købmagergade 53, 3.
Certified Advisor: Keswick Global AG, + 43 1 740 408045 , E-mail: info@keswickglobal.com
About BRAIN+ [BRAINP]
The mission of Brain+ is to restore patients’ independence and quality of life by treating and detecting cognitive decline in Alzheimer’s disease and dementia through software-as-medicine applications. Brain+ has developed a set of software-as-medicine technologies, which enable the Company to create a unique and differentiated product offering. These technologies, combined with a strong clinical pipeline, puts Brain+ in a strong position to grow towards a market leader position in the Digital Therapeutics (DTx) space.
